Biologic agents for treating ankylosing spondylitis: Beyond TNFα antagonists

Joint Bone Spine

Volumn 78, Issue 6, 2011, Pages 542-544

  Wendling, Daniel ^a   Prati, Clément ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Abatacept; Ankylosing spondylitis; Biotherapies; IL 17 antagonists; Rituximab; Tocilizumab

Indexed keywords

ABATACEPT; INTERLEUKIN 17; INTERLEUKIN 6; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SARILUMAB; SECUKINUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB;

ABSENCE OF SIDE EFFECTS; ANKYLOSING SPONDYLITIS; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TARGETING; EDITORIAL; HUMAN; IMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; HUMANS; INTERLEUKIN-12; INTERLEUKIN-17; INTERLEUKIN-6; SIGNAL TRANSDUCTION; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855974706     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.05.023     Document Type: Editorial

References (23)

1. McLeod C., Bagust A., Boland A., et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess. 2007, 11:1-158.
2. Gérard S., le Goff B., Maugars Y., et al. Six-month response to anti-TNF drugs in axial spondylarthropathy according to the fulfillment or not of New-York criteria for ankylosing spondylitis or French recommendations for anti-TNF use. A "real life" retrospective study on 175 patients. Joint Bone Spine. 2008, 75:680-687.
3. Griffoul I., Giraudeau B., Mulleman D., et al. Infliximab for treating axial spondylarthropathy in everyday practice. Joint Bone Spine. 2009, 76:39-43.
4. Wendling D., Prati C., Goupille P., et al. Optimizing anti TNF therapy in ankylosing spondylitis. Why and how?. Joint Bone Spine 2011, 78:225-227.
5. Kemta Lepka F., Farrenq V., Canoui-Poitrine, et al. Lack of efficacy of abatacept in axial spondylarthropathies refractory to Tumor-Necrosis-Factor inhibition. Joint Bone Spine 2011, 10.1016/j.jbspin.2011.02.018.
6. Olivieri I., D'Angelo S., Mennillo G.A., et al. Abatacept in spondyloarthritis refractory to tumour necrosis factor alpha inhibition. Ann Rheum Dis 2009, 68:151-152.
7. Song I.H., Heldmann F., Rudwaleit M., et al. Treatment of active ankylosing spondylitis with abatacept. An open label 24-week study. Ann Rheum Dis 2010, 69(Suppl. 3):60.
8. Wendling D. Interleukin-1: a new therapeutic target for ankylosing spondylitis?. Joint Bone Spine. 2005, 72:357-358.
9. Nocturne G., Dougados M., Constantin A., et al. Rituximab in the spondyloarthropathies: data of eight patients followed up in the French Autoimmunity and Rituximab (AIR) registry. Ann Rheum Dis. 2010, 69:471-472.
10. Song I.H., Heldmann F., Rudwaleit M., et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum. 2010, 62:1290-1297.
11. Wendling D. Interleukin-6 as a therapeutic target in spondylarthritis. Arthritis Care Res (Hoboken). 2010, 62:745.
12. Wendling D., Racadot E., Toussirot E., et al. Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy. Br J Rheumatol. 1996, 35:1330.
13. Wendling D., Bossert M., Prati C. Short-term effect of IL-6 inhibition in spondylarthritis. Joint Bone Spine 2010, 77:624-625.
14. Tanaka T., Kuwahara Y., Shima Y., et al. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Arthritis Rheum. 2009, 61:1762-1764.
15. Shima Y., Tomita T., Ishii T., et al. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. Mod Rheumatol 2011, 10;1007/s10165-011-0416-9.
16. Brulhart L., Nissen M.J., Chevallier P., et al. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint Bone Spine. 2010, 77:625-626.
17. Henes J.C., Horger M., Guenaydin I., et al. Mixed response to tocilizumab for ankylosing spondylitis. Ann Rheum Dis. 2010, 69:2217-2218.
18. Wendling D. Interleukin 23: a key cytokine in chronic inflammatory disease. Joint Bone Spine. 2008, 75:517-519.
19. Wendling D. IL-23 and IL-17 in ankylosing spondylitis. Rheumatol Int. 2010, 30:1547.
20. Wendling D., Cedoz J.P., Racadot E., et al. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine. 2007, 74:304-305.
21. Wendling D., Cedoz J.P., Racadot E. Serum and synovial fluid levels of p40 IL12/23 in spondyloarthropathy patients. Clin Rheumatol. 2009, 28:187-190.
22. Gottlieb A., Menter A., Mendelsohn A., et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009, 373:633-640.
23. Baeten D., Sieper J., Emery P., et al. The anti-IL17A monoclonal antibody Secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Arthritis Rheum 2010, 62:3840-3841.